Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sickle Cell Disease - Overview
Sickle Cell Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sickle Cell Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sickle Cell Disease - Companies Involved in Therapeutics Development
Sickle Cell Disease - Drug Profiles
Sickle Cell Disease - Dormant Projects
Sickle Cell Disease - Discontinued Products
Sickle Cell Disease - Product Development Milestones
Featured News & Press Releases
Jun 18, 2022: Forma Therapeutics announces presentations at upcoming Hematology Conferences
Jun 11, 2022: Vertex and CRISPR Therapeutics present new data on more patients with longer follow-Up treated with exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
Jun 11, 2022: Vertex and CRISPR Therapeutics announce acceptance of late-breaking abstract for CTX001 at the 2022 Annual European Hematology Association (EHA) Congress
Jun 10, 2022: GBT presents positive new real-world evidence data at EHA2022 Congress further supporting clinical use of Oxbryta (voxelotor) in sickle cell disease
Jun 10, 2022: Fulcrum Therapeutics announces Proof-of-Concept for FTX-6058 in sickle cell disease based on initial data from the ongoing phase 1b trial
Jun 06, 2022: GBT’s inclacumab receives U.S. FDA orphan drug and rare pediatric disease desigtions for the treatment of sickle cell disease
May 12, 2022: Editas Medicine receives FDA Orphan Drug Desigtion for EDIT-301 for the treatment of beta thalassemia
May 12, 2022: Fulcrum Therapeutics to present initial data from phase 1b trial of FTX-6058 in adults living with sickle cell disease at the European Hematology Association (EHA) Hybrid Congress in Vien, Austria
May 12, 2022: Agios to present clinical and translatiol data at the European Hematology Association Annual Congress
Apr 11, 2022: Emmaus Life Sciences announces launch of full-service telehealth solution
Apr 07, 2022: Emmaus Life Sciences presented positive real-world data on the efficacy of Endari in preventing acute complications from sickle cell disease at the 62nd Annual Scientific Meeting of the British Society for Haematology
Mar 29, 2022: Emmaus Life Sciences announces Endari to be added to the Florida Medicaid Preferred Drug List
Mar 23, 2022: Emmaus Life Sciences receives U.A.E. Marketing Authorization for Endari
Mar 04, 2022: Emmaus Life Sciences’ Real World Data on Endari accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology
Mar 02, 2022: Nicox’s Partner Fera Pharmaceuticals obtains Orphan Drug Desigtion from the U.S. FDA for proxcinod for the treatment of sickle cell disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Sickle Cell Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Sickle Cell Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Sickle Cell Disease - Pipeline by Afimmune Biopharma Ltd, 2022
Sickle Cell Disease - Pipeline by Agios Pharmaceuticals Inc, 2022
Sickle Cell Disease - Pipeline by Alfasigma SpA, 2022
Sickle Cell Disease - Pipeline by Alkermes Plc, 2022
Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, 2022
Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, 2022
Sickle Cell Disease - Pipeline by AntiRadical Therapeutics LLC, 2022
Sickle Cell Disease - Pipeline by Ascentage Pharma Group Inc, 2022
Sickle Cell Disease - Pipeline by Asklepion Pharmaceuticals LLC, 2022
Sickle Cell Disease - Pipeline by Aviceda Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Axcella Health Inc, 2022
Sickle Cell Disease - Pipeline by Beam Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Bellicum Pharmaceuticals Inc, 2022
Sickle Cell Disease - Pipeline by bluebird bio Inc, 2022
Sickle Cell Disease - Pipeline by Brooklyn ImmunoTherapeutics Inc, 2022
Sickle Cell Disease - Pipeline by C4X Discovery Holdings Plc, 2022
Sickle Cell Disease - Pipeline by Cannabis Science Inc, 2022
Sickle Cell Disease - Pipeline by Cell Source Inc, 2022
Sickle Cell Disease - Pipeline by Cellectis SA, 2022
Sickle Cell Disease - Pipeline by Cetya Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Sickle Cell Disease - Pipeline by CRISPR Therapeutics AG, 2022
Sickle Cell Disease - Pipeline by CSL Ltd, 2022
Sickle Cell Disease - Pipeline by Cyclerion Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Daiichi Sankyo Co Ltd, 2022
Sickle Cell Disease - Pipeline by Editas Medicine Inc, 2022
Sickle Cell Disease - Pipeline by Emmaus Life Sciences Inc, 2022
Sickle Cell Disease - Pipeline by Epidestiny Inc, 2022
Sickle Cell Disease - Pipeline by Epizyme Inc, 2022
Sickle Cell Disease - Pipeline by Forma Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Fulcrum Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Functional Fluidics LLC, 2022
Sickle Cell Disease - Pipeline by Gamida Cell Ltd, 2022
Sickle Cell Disease - Pipeline by Garuda Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Gilead Sciences Inc, 2022
Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Glycan Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by GlycoMimetics Inc, 2022
Sickle Cell Disease - Pipeline by Graphite Bio Inc, 2022
Sickle Cell Disease - Pipeline by GreenLight Biosciences Holdings PBC, 2022
Sickle Cell Disease - Pipeline by Guangzhou Dazhou Biomedical Technology Co Ltd, 2022
Sickle Cell Disease - Pipeline by Hartis Pharma SA, 2022
Sickle Cell Disease - Pipeline by Hillhurst Biopharmaceuticals Inc, 2022
Sickle Cell Disease - Pipeline by Homology Medicines Inc, 2022
Sickle Cell Disease - Pipeline by IHP Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by IllExcor Therapeutics LLC, 2022
Sickle Cell Disease - Pipeline by Imago BioSciences Inc, 2022
Sickle Cell Disease - Pipeline by Intellia Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Invenux LLC, 2022
Sickle Cell Disease - Pipeline by Jasper Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Jazz Pharmaceuticals Plc, 2022
Sickle Cell Disease - Pipeline by KM Biologics Co Ltd, 2022
Sickle Cell Disease - Pipeline by Medeor Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Merck & Co Inc, 2022
Sickle Cell Disease - Pipeline by Micelle BioPharma Inc, 2022
Sickle Cell Disease - Pipeline by MimeTech Srl, 2022
Sickle Cell Disease - Pipeline by Mind Biosciences LLC, 2022
Sickle Cell Disease - Pipeline by Mitobridge Inc, 2022
Sickle Cell Disease - Pipeline by Modus Therapeutics AB, 2022
Sickle Cell Disease - Pipeline by Molecules For Health Inc, 2022
Sickle Cell Disease - Pipeline by Monte Rosa Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by NicOx SA, 2022
Sickle Cell Disease - Pipeline by Novartis AG, 2022
Sickle Cell Disease - Pipeline by NuvOx Pharma LLC, 2022
Sickle Cell Disease - Pipeline by Oryzon Genomics SA, 2022
Sickle Cell Disease - Pipeline by Pfizer Inc, 2022
Sickle Cell Disease - Pipeline by PHD Biosciences, 2022
Sickle Cell Disease - Pipeline by Phoenicia Biosciences Inc, 2022
Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, 2022
Sickle Cell Disease - Pipeline by Rare Partners Srl, 2022
Sickle Cell Disease - Pipeline by Regenacy Pharmaceuticals LLC, 2022
Sickle Cell Disease - Pipeline by ReNeuroGen LLC, 2022
Sickle Cell Disease - Pipeline by San Rocco Therapeutics LLC, 2022
Sickle Cell Disease - Pipeline by Sana Biotechnology Inc, 2022
Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Secura Bio Inc, 2022
Sickle Cell Disease - Pipeline by Shanghai Bendao Gene Technology Co Ltd, 2022
Sickle Cell Disease - Pipeline by Syros Pharmaceuticals Inc, 2022
Sickle Cell Disease - Pipeline by Tarus Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by ThioLab LLC, 2022
Sickle Cell Disease - Pipeline by TransThera Sciences (Nanjing) Inc, 2022
Sickle Cell Disease - Pipeline by Vanguard Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Vera Therapeutics Inc, 2022
Sickle Cell Disease - Pipeline by Vertex Pharmaceuticals Inc, 2022
Sickle Cell Disease - Pipeline by Vifor Pharma Ltd, 2022
Sickle Cell Disease - Dormant Projects, 2022
Sickle Cell Disease - Dormant Projects, 2022 (Contd..1)
Sickle Cell Disease - Dormant Projects, 2022 (Contd..2)
Sickle Cell Disease - Dormant Projects, 2022 (Contd..3)
Sickle Cell Disease - Discontinued Products, 2022